{
  "model": "qwen/qwen3.6-35b-a3b",
  "started_at": "2026-06-10T02:31:17.009Z",
  "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft a\nhigh-conviction idea, draft a clearly labeled paper-tracked research idea,\nor skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes normal\nrecommendation-grade ideas rarely and only when something clears a high bar.\nMost dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": <num> }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\nPaper-tracked ideas are a separate measurement lane: they are zero-position,\nlow-confidence research setups used to learn whether the model's medium-grade\nsignals work over time. They must never read like a buy/sell recommendation.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n   • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n     last 90 days totaling ≥ $500K\n   • +3 pts if CEO is among the buyers\n   • +3 pts if CFO is among the buyers\n   • +2 pts if total purchases > $5M\n   • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n     Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n   • +3 pts if it's in the manager's top-3 positions\n   • 2 pts for politician STOCK Act recent buy\n   • +1 pt if multiple unrelated members bought within 30 days\n   • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n   • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n     and flow_strength ∈ {moderate, strong}\n   • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n   • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n   • 1 pt: large OI building at a defended price level\n   • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n     without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n   • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n   • 8 pts: pending product launch / FDA / contract milestone in horizon\n   • 5 pts: recent guidance raise (last 90 days)\n   • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n     to this name in $)\n   Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n   • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n     earnings)\n   • 4 pts: EV/EBITDA ≥ 30% below sector median\n   • 4 pts: FCF yield ≥ 7% with stable FCF\n   • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n   Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n   • 5 pts: ROIC ≥ 15% (or trending there)\n   • 5 pts: gross margin expanding ≥ 3pp YoY\n   • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n   • 3 pts: above both 50DMA and 200DMA\n   • 4 pts: 12-1 month price return positive AND beating sector\n   • 2 pts: RSI 14 in 40-65 zone\n   • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n   \"core\"        — market_cap > $5B. Standard methodology sizing.\n   \"asymmetric\"  — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n                   bets lose money or go to zero; the few that work pay\n                   for the rest. Position sizing is far more conservative\n                   to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n  CORE risk_class:\n   ≥ 80    Publish, confidence 5, position size cap 4-5%\n   70-79   Publish, confidence 4, position size cap 2.5-3.0%\n   60-69   Publish, confidence 3, position size cap 1.5-2.0%\n   45-59   Paper-track if no hard anti-signal and the thesis is specific,\n           measurable, and falsifiable; otherwise skip\n   < 45    Skip\n\n  ASYMMETRIC risk_class — strict sizing:\n   ≥ 80    Publish, confidence 5, position size cap 1.5%\n   70-79   Publish, confidence 4, position size cap 1.0%\n   60-69   Publish, confidence 3, position size cap 0.5%\n   45-59   Paper-track only if there is a concrete dated catalyst or\n           measurable event path; otherwise skip\n   < 45    Skip\n   Structure must be long_stock (options structures are wrong shape for\n   moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n   • Going-concern audit qualification\n   • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n   • Customer concentration > 30%\n   • Convertible/warrant overhang creating dilution > 10% of float\n   • Accounting irregularities (restatements, auditor changes)\n   • Avg daily volume < $5M (liquidity gate)\n   • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nPAPER-TRACKING LANE (educational measurement, not advice)\n\nUse this lane for score 45-59 dossiers that are not strong enough for a\nnormal publication but are specific enough to evaluate later. Requirements:\n   • draft.paper_track MUST be true\n   • headline MUST begin with \"Paper Track:\"\n   • thesis_short MUST explicitly say this is a paper-tracked research setup,\n     not an actionable recommendation\n   • risk.position_size_pct MUST be 0\n   • confidence MUST be 1 or 2 (2 only when score ≥55)\n   • exit.time_horizon_months MUST be present so Monitor can close it\n   • use long_stock unless the dossier gives complete, current option\n     contract data for the chosen income structure\n\nDo not paper-track dossiers with methodology anti-signals, stale numbers,\nmissing sources, unverified catalyst dates, or generic \"cheap/AI/tailwind\"\nstories. Skip those.\n\nUPSIDE TARGET\n\nThe desk is looking for setups with a plausible 20%+ return target. For\nlong_stock, exit.target_price should be at least 20% above entry.price_at_idea\nunless the idea is explicitly a paper-tracked post-event study. If the\nsource-backed upside is less than 20%, skip rather than publishing a low-upside\nidea.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n  verdict='promising'              → long_stock | csp (for asymmetric long)\n  verdict='range_bound_or_income'  → cc | strangle | csp on pullback\n                                     (DON'T default to long_stock — Scout\n                                      already said this isn't an asymmetric\n                                      long. Look at IV elevated → strangle;\n                                      stock at 52w high, fundamentals healthy\n                                      → cc against implicit long; pullback\n                                      thesis with cash → csp)\n  verdict='bearish_setup'          → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n   long_stock   — multi-quarter asymmetric thesis, IV not elevated, want\n                  full upside participation\n   csp          — bullish, want to own at strike, IV elevated, ann yield ≥15%\n   cc           — range-bound or mildly bullish, IV elevated, on top of long\n                  stock leg, if-called return ≥15% ann\n   strangle     — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n                  put. Need: comfortable owning at put_strike, no parabolic\n                  upside expectation. Ann yield ≥12%. Compute and emit\n                  breakeven_high (call_strike + total_premium) and\n                  breakeven_low (put_strike - total_premium).\n   naked_put    — same setup as CSP but using margin. ~2x yield, margin call\n                  risk. Only for margin-equipped accounts. Note explicitly.\n   naked_call   — bearish setup with elevated IV. UNCAPPED loss if rally.\n                  Confidence ceiling 4 (Compliance enforces). Requires\n                  explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n  {\n    \"skip\": true,\n    \"score\": <0-100 composite>,\n    \"score_breakdown\": {\n      \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n      \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n    },\n    \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n  }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n  \"skip\": false,\n  \"score\": <0-100 composite>,\n  \"score_breakdown\": {\n    \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n    \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n  },\n  \"draft\": {\n    \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n    \"paper_track\": false,\n    \"symbol\": \"TICKER\",\n    \"company\": \"Full name\",\n    \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n    \"risk_class\": \"core\" | \"asymmetric\",\n    \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n    \"thesis_short\": \"1 sentence — why this trade exists.\",\n    \"thesis_long\": [\n      \"Opening paragraph framing the setup.\",\n      \"## Catalyst\",\n      \"Detailed catalyst narrative.\",\n      \"## Why the market is mispricing this\",\n      \"Edge explanation, citing dossier facts.\",\n      \"## Numbers\",\n      \"- Bullet 1 with concrete numbers from the dossier\",\n      \"- Bullet 2\",\n      \"## Risk\",\n      \"Honest description of what could go wrong.\"\n    ],\n    \"structure\": {\n      \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n      \"long_stock\":   { \"entry_zone_low\": <num>, \"entry_zone_high\": <num>, \"shares_per_unit\": 100 },\n      \"csp\":          { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"if_assigned_basis\": <num> },\n      \"cc\":           { \"underlying_basis\": <num>, \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"if_called_return_pct\": <num> },\n      \"strangle\":     { \"call_strike\": <num>, \"put_strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": <num>, \"put_premium_target\": <num>, \"total_premium_target\": <num>, \"breakeven_high\": <num>, \"breakeven_low\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_note\": \"...\" },\n      \"naked_put\":    { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss_per_contract\": <num>, \"margin_estimate_per_contract\": <num>, \"warning\": \"...\" },\n      \"naked_call\":   { \"strike\": <num>, \"expiry\": \"YYYY-MM-DD\", \"premium_target\": <num>, \"annualized_yield_pct\": <num>, \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n    },\n    \"entry\": {\n      \"price_at_idea\": <last_close from dossier>,\n      \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n    },\n    \"exit\": {\n      \"target_price\": <num or null for options structures>,\n      \"time_horizon_months\": <int 3-12>,\n      \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n    },\n    \"risk\": {\n      \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n      \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n      \"position_size_pct\": <0.0 for paper_track, otherwise 0.5 to 5.0 conviction-weighted>\n    },\n    \"sources\": [\n      { \"label\": \"...\", \"url\": \"...\" }\n    ],\n    \"confidence\": <1-5, conservative>,\n    \"analyst\": \"research-desk\",\n    \"scout_model\": \"minimax/minimax-m2.7\",\n    \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n    \"devils_advocate_verdict\": null\n  }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.",
  "user_prompt": "CURRENT DATE: 2026-06-10. THE YEAR IS 2026.\nDATE RULES — read before writing ANY date:\n  - Every option expiry, earnings date, catalyst date, and DTE you state MUST use the year 2026 or later. Do NOT write 2025 dates — your training prior is stale.\n  - Every option expiry MUST be a real FUTURE date relative to 2026-06-10. Copy expiries verbatim from options_expiries()/the dossier — never infer a year from memory.\n  - Before writing a date, check it: if it is earlier than 2026-06-10, it is WRONG — re-read the live tool output.\n\nHere is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n  \"symbol\": \"ILMN\",\n  \"company\": \"Illumina, Inc.\",\n  \"investigation_summary\": \"The Form 4 cluster triggering this investigation is primarily driven by Keith Meister (Corvex Management) converting equity swaps into actual shares and aggressively selling them at current elevated prices — over 700,000 shares sold May-June 2026 in the $140-165 range. This is a DISTRIBUTION pattern from an activist/large holder, not a bullish accumulation signal. Separately, a SVP (Patricia Leckman) made small sales near all-time highs. Meanwhile, fundamentals are strong — Q1 2026 EPS beat by 9%, multiple oncology product launches in May-June 2026 (StrataMap Spatial Solution, fireflyGO automation platform with SPT Labtech, whole-genome WGS MRD research kit, IDT DRAGEN integration), and NovaSeq X adoption accelerating. The stock has run +56% YTD and sits within ~5% of its 52-week high ($160 vs $177). Forward P/E of 27x is elevated versus sector peers, but ILMN's dominance in sequencing justifies a premium. Earnings on July 30 could be a near-term catalyst or inflection point.\",\n  \"verdict\": \"range_bound_or_income\",\n  \"confidence_in_data\": 4,\n  \"structure_hints\": [\n    \"cc\",\n    \"strangle\",\n    \"csp\"\n  ],\n  \"business_snapshot\": \"Illumina is the dominant global provider of DNA sequencing and array-based genetic analysis tools, serving academic research institutions, pharmaceutical/biotech companies, clinical laboratories, and government entities across 115+ countries. FY2025 revenue was ~$4.39B with a gross margin of 68%. The company generates the majority of revenue from consumables (reagents/flow cells) tied to its installed base of sequencing instruments — NovaSeq X series is the current flagship platform driving instrument and consumable sales. Illumina completed two significant strategic actions recently: divested GRAIL (cancer screening spinoff) removing a major overhang, and acquired SomaLogic in January 2026 for ~$98M, expanding into proteomics via protein analysis platforms. The competitive moat lies in the installed base, proprietary chemistry, and software ecosystem (DRAGEN secondary analysis). Risks include China regulatory exposure (included on 'unreliable entities list' concern), NIH funding sensitivity to federal budget changes, tariff pressures on manufacturing costs, and deep concentration risk in a limited number of large genomic centers.\",\n  \"scoring_inputs\": {\n    \"smart_money\": {\n      \"insider_open_market_purchases_90d\": [\n        {\n          \"insider\": \"David P. King\",\n          \"role\": \"Director\",\n          \"amount_usd\": 299999,\n          \"date\": \"2026-05-21\",\n          \"source_url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000121/xslF345X06/form4.xml\"\n        }\n      ],\n      \"insider_open_market_total_usd_90d\": 300000,\n      \"distinct_insider_buyers_90d\": 1,\n      \"ceo_buy_present\": false,\n      \"cfo_buy_present\": false,\n      \"material_insider_selling_90d_usd\": 110000000\n    },\n    \"options_flow\": {\n      \"whale_call_blocks_otm\": 0,\n      \"flow_directional_bias\": \"bullish\",\n      \"net_dollar_bias_pct\": 37.6\n    }\n  },\n  \"catalyst\": {\n    \"next_earnings_date\": \"2026-07-30T20:00:00.000Z\",\n    \"recent_eps_surprise_pattern\": \"4 consecutive positive EPS beats — Q1 2026 +9%, Q4 2025 +9.7%, Q3 2025 +14.7%, Q2 2025 +17.7%\",\n    \"guidance_raise_in_last_90d\": false,\n    \"named_catalysts\": [\n      {\n        \"type\": \"product\",\n        \"description\": \"StrataMap Spatial Solution launch — end-to-end spatial whole transcriptome research tool for oncology and neuroscience (June 8, 2026)\",\n        \"date_or_window\": \"June 8, 2026\",\n        \"source_urls\": [\n          \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-launches-stratamap-spatial-solution-131500033.html\"\n        ],\n        \"directional_bias\": \"bullish\"\n      },\n      {\n        \"type\": \"product\",\n        \"description\": \"fireflyGO automation platform with SPT Labtech — benchtop liquid handling for targeted oncology workflows, integrated with MiSeq i100 Series (May 28, 2026)\",\n        \"date_or_window\": \"May 28, 2026\",\n        \"source_urls\": [\n          \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-spt-labtech-unveil-fireflygo-163000407.html\"\n        ],\n        \"directional_bias\": \"bullish\"\n      },\n      {\n        \"type\": \"product\",\n        \"description\": \"First distributed whole-genome sequencing (WGS) MRD research kit for molecular residual disease — validated with Mayo Clinic and Bristol Myers Squibb, early access launched May 28, 2026\",\n        \"date_or_window\": \"May 28, 2026\",\n        \"source_urls\": [\n          \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-introduces-first-distributed-whole-131500045.html\"\n        ],\n        \"directional_bias\": \"bullish\"\n      },\n      {\n        \"type\": \"product\",\n        \"description\": \"IDT xGen FFPE and cfDNA workflow integration with Illumina DRAGEN secondary analysis platform — end-to-end somatic oncology research solution (May-June 2026)\",\n        \"date_or_window\": \"May-June 2026\",\n        \"source_urls\": [\n          \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-ilmn-deeper-idt-dragen-191328386.html\"\n        ],\n        \"directional_bias\": \"bullish\"\n      },\n      {\n        \"type\": \"product\",\n        \"description\": \"Illumina Connected Insights software expansion with IDT integration for oncology interpretation\",\n        \"date_or_window\": \"2026\",\n        \"source_urls\": [\n          \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-oncology-launches-put-product-160513872.html\"\n        ],\n        \"directional_bias\": \"ambiguous\"\n      }\n    ]\n  },\n  \"mispricing\": {\n    \"forward_pe\": 27.02,\n    \"sector_median_forward_pe\": 24,\n    \"ev_to_ebitda\": 22.17,\n    \"fcf_yield_pct\": 3.5,\n    \"narrative\": \"ILMN trades at a 12-15% forward P/E premium to sector, reflecting its dominant ~80% share of the sequencing market and recurring consumables revenue from its installed base. The premium is defensible given competitive moat but leaves little room for disappointment. FCF yield of 3.5% is modest.\"\n  },\n  \"quality\": {\n    \"roic_pct\": null,\n    \"gross_margin_trend_pp_yoy\": \"+1pp (FY2024: 67.2% to FY2025: 68.3%)\",\n    \"net_debt_to_ebitda\": null,\n    \"balance_sheet_grade\": \"B\"\n  },\n  \"technical\": {\n    \"above_50dma\": true,\n    \"above_200dma\": null,\n    \"rsi_14\": 61.1,\n    \"macd_recent_bullish_cross\": true,\n    \"12_1_momentum_vs_sector_pct\": 20\n  },\n  \"price_context\": {\n    \"last_close\": 160.03,\n    \"ytd_return_pct\": 56.49,\n    \"from_52w_high_pct\": 9.7\n  },\n  \"filings_reviewed\": [\n    {\n      \"form\": \"10-K\",\n      \"filed\": \"2026-02-12\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000024/ilmn-20251228.htm\",\n      \"key_takeaways\": [\n        \"FY2025 revenue $4.39B (+4.8% YoY), gross margin 68.3%, operating margin 18.3%. GRAIL divested Q2 2025 — eliminated contingent liability CVR exposure. Term notes outstanding: $499M current portion due 2026, $1.49B long-term. Debt-to-equity 95% is elevated. SomaLogic acquisition closed Jan 30, 2026 ($98M) for proteomics expansion.\"\n      ]\n    },\n    {\n      \"form\": \"10-Q\",\n      \"filed\": \"2026-05-04\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm\",\n      \"key_takeaways\": [\n        \"Q1 2026 revenue $1.091B (+4.8% YoY), EPS $1.15 vs estimate $1.055 (+9% beat). Cash $1.089B vs $1.418B end of FY2025 — used ~$329M for SomaLogic and share repurchases. Operating cash flow strong at $291M in Q1. Goodwill jumped from $1,113M to $1,284M (SomaLogic acquisition). Debt: $499M current + $1,490M long-term term debt.\"\n      ]\n    },\n    {\n      \"form\": \"8-K\",\n      \"filed\": \"2026-05-26\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000124/ilmn-20260521.htm\",\n      \"key_takeaways\": [\n        \"May 21, 2026 annual meeting results: all 9 director nominees elected. Keith Meister re-elected with only 127.26M votes FOR vs 10.43M broker non-votes — notable that ~3.1M voted AGAINST him suggesting some institutional dissatisfaction.\"\n      ]\n    }\n  ],\n  \"options_context\": {\n    \"expiries_examined\": [\n      \"2026-07-17\",\n      \"2026-09-18\"\n    ],\n    \"iv_summary\": \"ATM IV July 17 (37 DTE): call side 50%, put side 47.7%. ATM IV September 18: ~46-48% range. IV is elevated but not extreme — consistent with a high-beta growth healthcare name near recent highs.\",\n    \"notable_skew_or_flow\": \"Net call-biased flow (+$40K call vs $33K put); top OI on calls at strikes 175 (OI=132) and puts at 180 (OI=78). Put/call ratio of 0.64 suggests bullish lean but no whale blocks detected in current feed.\"\n  },\n  \"competitive_landscape\": \"Illumina holds ~80% of the global DNA sequencing market — a near-monopoly in short-read sequencing. Key competitors: Oxford Nanopore Technologies (ONT, long-read alternative gaining share), Pacific Biosciences (PacBio, HiFi long-read for structural variants), Thermo Fisher Scientific (targeted qPCR arrays) and Agilent (microarrays). In proteomics, SomaLogic acquisition positions ILMN against Olink. NovaSeq X series ($20K list price with $10-15K annual reagent contract) is the current flagship driving instrument placements in large genomic centers.\",\n  \"key_risks\": [\n    \"Keith Meister / Corvex actively distributing shares — 700K+ sold May-June 2026 at $140-$165 (bearish signal from largest institutional holder). Patricia Leckman selling on same dates near all-time highs. Elevated forward P/E of 27x vs sector leaves no margin for error if NovaSeq X adoption slows or clinical sequencing demand softens.\",\n    \"China regulatory exposure: Q4 FY2025 risk factor disclosed inclusion on 'unreliable entities' list — potential revenue impact from China operations (Greater China segment historically ~7-10% of revenue).\",\n    \"High debt load ($1.99B total) at 95% D/E. Current portion of $499M due in 2026 creates near-term refinancing risk.\",\n    \"NIH funding sensitivity: federal budget changes/cancellations could reduce demand from academic/government customers who represent major installed base.\",\n    \"Stock up +56% YTD, within 10% of 52-week high — momentum is extended and limits upside potential near-term.\"\n  ],\n  \"what_the_market_might_be_missing\": \"The Corvex swap-to-share conversion pattern is actually UNDERREPORTED in significance by retail-focused news. Keith Meister (Corvex) held economic exposure via equity swaps at $102.82 cost basis since 2022-2023, then systematically converted to physical shares and sold into the +56% YTD rally — unloading ~700K+ shares May-June alone. This is a sophisticated investor taking profits after a massive run, not adding. The Form 4 cluster that triggered this investigation (5 filings / 14 days) is actually predominantly SELLING, not buying. Market may be treating the Keith Meister 'cluster' as bullish activism when it's actually distribution from an informed holder.\",\n  \"anti_signals_present\": [\n    \"dilution\",\n    \"concentration\"\n  ],\n  \"sources\": [\n    {\n      \"label\": \"Illumina Q1 2026 10-Q (filed May 4, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000092/ilmn-20260329.htm\"\n    },\n    {\n      \"label\": \"Keith Meister Form 4 (swap conversion + sales, filed June 1, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000101143826000371/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Keith Meister Form 4 (May 7-14 swap terminations + sales, filed May 11-14, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000101143826000273/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Keith Meister Form 4 (partial swap termination May 12, filed May 14, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000101143826000335/xslF345X06/form4.xml\"\n    },\n    {\n      \"label\": \"Illumina Q1 2026 earnings beat + product launches news\",\n      \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/illumina-ilmn-valuation-check-oncology-180829817.html\"\n    },\n    {\n      \"label\": \"Annual Meeting Results 8-K (May 21, 2026)\",\n      \"url\": \"https://www.sec.gov/Archives/edgar/data/1110803/000111080326000124/ilmn-20260521.htm\"\n    }\n  ],\n  \"unfetched_signals\": [\n    \"13f_deltas\",\n    \"politician_trades\",\n    \"sentiment_score\"\n  ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude <think>...</think> reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.",
  "completions": [
    {
      "ts": "2026-06-10T02:32:16.967Z",
      "raw_content": "<think>The dossier is for ILMN (Illumina, Inc.).\nScout's verdict: `range_bound_or_income`\nScoring inputs:\n- Smart Money: 1 insider buyer ($300k), CEO/CFO not buyers. Material insider selling: $110M. Penalty: -10 pts. Score: 0 (base 0, only 1 pt for distinct buyer? Wait, rubric says 10 pts if 3+ buyers totaling >=$500K. Here only 1 buyer, $300k total. So 0 pts for smart money. Selling penalty applies: -10 pts. Score: 0 or -10? I'll cap at 0 for this category, or just give 0. Actually, rubric says \"Penalty: -10 pts if material insider SELLING > BUYING in dollars\". I'll give 0 for smart_money.)\n- Options Flow: 0 whale call blocks. Net dollar bias 37.6% (>30, +2 pts). Skew? Not explicitly bullish call IV > put IV, but ATM IV call 50%, put 47.7%. +3 pts? Maybe not. I'll give 2 pts for net_dollar_bias > 30.\n- Catalyst: Earnings July 30 (within 90d) + 4 consecutive positive EPS beats. +10 pts. Product launches in May-June 2026. +8 pts? Cap at 25. I'll give 18.\n- Mispricing: Forward P/E 27 vs sector 24. Not below. EV/EBITDA 22.17. FCF yield 3.5%. SOTP gap? None. Score: 0.\n- Quality: ROIC null. Gross margin +1pp YoY (<3pp). Net debt/EBITDA null. Score: 0.\n- Technical: Above 50DMA (+3). 12-1 momentum vs sector +20% (+4). RSI 61.1 (+2). MACD bullish cross (+1). Total: 10.\nTotal Score: ~0 (smart) + 2 (opt) + 18 (catalyst) + 0 (mispricing) + 0 (quality) + 10 (tech) = 30.\nWait, let's be generous but accurate:\nSmart money: 0 (selling dominates)\nOptions: 2\nCatalyst: 18 (earnings beat streak + product launches)\nMispricing: 0\nQuality: 0\nTechnical: 10\nTotal: ~30.\nAnti-signals present: \"dilution\", \"concentration\". The dossier mentions \"Customer concentration > 30%\" as a potential anti-signal gate, but the dossier says \"deep concentration risk in a limited number of large genomic centers.\" I will treat anti-signals as a reason to skip.\nAlso, the dossier explicitly says: \"The Form 4 cluster triggering this investigation is primarily driven by Keith Meister... selling... DISTRIBUTION pattern... Market may be treating the Keith Meister 'cluster' as bullish activism when it's actually distribution from an informed holder.\"\nThis is a strong bearish/distribution signal. The stock is up 56% YTD, near 52-week high. Forward P/E is elevated. No clear asymmetric long opportunity. Income structures (CC, strangle, CSP) are hinted, but the anti-signals (dilution, concentration) and heavy insider selling make this a skip.\nAlso, the prompt says: \"If scoring_inputs has anti_signals_present non-empty, treat each entry as a gate; skip unless you can articulate WHY it doesn't apply to this case.\"\nAnti-signals: \"dilution\", \"concentration\".\nDilution: The dossier mentions \"Convertibles/warrant overhang creating dilution > 10% of float\" is an anti-signal. The dossier says \"elevated debt load ($1.99B total) ... Current portion of $499M due in 2026 creates near-term refinancing risk.\" Not strictly dilution anti-signal, but \"dilution\" is listed.\nConcentration: \"Customer concentration > 30%\" is an anti-signal. Dossier says \"deep concentration risk in a limited number of large genomic centers.\"\nGiven the heavy insider selling ($110M vs $300k buying), elevated valuation, and anti-signals, this should be skipped.\nScore will be low. I will output a skip JSON.\n\nLet's calculate score carefully:\nA. Smart Money: 0 (selling > buying, penalty -10, cap at 0)\nB. Options Flow: 2 (net_dollar_bias 37.6 > 30)\nC. Catalyst: 18 (earnings within 90d + 4 beats = 10; product launches = 8)\nD. Mispricing: 0 (P/E premium, not discount)\nE. Quality: 0 (ROIC null, margin +1pp, debt unknown)\nF. Technical: 10 (above 50DMA=3, momentum beat sector=4, RSI 40-65=2, MACD cross=1)\nTotal: 30.\nAnti-signals present: dilution, concentration.\nVerdict: range_bound_or_income. But with $110M insider selling and elevated valuation, income structures are risky. The prompt says \"OPTION B (skip) IS THE EXPECTED DEFAULT.\"\nI will skip.\n\nReason: Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (concentration, dilution risk) outweigh the earnings catalyst and technical momentum, making income structures too risky given the extended run-up (+56% YTD) and elevated valuation.\n\nCheck thresholds: <45 -> Skip.\nOutput matches skip format.\nAll good.\nI will generate the JSON. \nWait, let's double check the scoring rubric for Smart Money:\n\"Penalty: −10 pts if material insider SELLING > BUYING in dollars\" -> I'll give 0 for this category since it goes negative.\nOptions: 2.\nCatalyst: 18.\nMispricing: 0.\nQuality: 0.\nTechnical: 10.\nTotal: 30.\nI'll output exactly the skip JSON.\nOne detail: \"anti_signals_present\": [\"dilution\", \"concentration\"]. I will mention these in the reason.\nReady. \nOutput matches requested format.\nProceed. \nSelf-Correction/Refinement during thought: \nCould I draft a paper track? Score is 30, which is <45. Skip is mandatory for <45.\nI will output the skip JSON.\nCheck format:\n{\n  \"skip\": true,\n  \"score\": 30,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.\"\n}\nMatches perfectly. No extra text. Valid JSON.\nProceeds. \nOutput Generation. \n[Done] \n(Self-Correction/Verification during generation prep)\nWait, the prompt says \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I'll just put 0 for smart_money since it's capped at 0 for the breakdown usually, or -10? The rubric says max 25, but doesn't specify floor. I'll put 0.\nScore breakdown sums to 30.\nAll good. \nOutput matches. \nProceeds. \n[Output Generation] -> *Proceeds*\n</think>\n\n{\n  \"skip\": true,\n  \"score\": 30,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.\"\n}",
      "cleaned_content": "{\n  \"skip\": true,\n  \"score\": 30,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.\"\n}",
      "tool_calls": null,
      "finish_reason": "stop"
    }
  ],
  "tool_results": [],
  "final_message": "{\n  \"skip\": true,\n  \"score\": 30,\n  \"score_breakdown\": {\n    \"smart_money\": 0,\n    \"options_flow\": 2,\n    \"catalyst\": 18,\n    \"mispricing\": 0,\n    \"quality\": 0,\n    \"technical\": 10\n  },\n  \"reason\": \"Heavy insider distribution ($110M sold vs $300K bought) and active anti-signals (customer concentration, dilution risk) outweigh the earnings catalyst and technical momentum. With the stock up 56% YTD at an elevated forward P/E, neither long nor income structures offer a favorable risk/reward profile.\"\n}",
  "tool_calls_total": 0,
  "walltime_ms": 59959,
  "stop_reason": "stop",
  "completed_at": "2026-06-10T02:32:16.968Z"
}